RogerBCohenMD

PubMed

• Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC.
  Margaret Stalker, Melina Marmarelis, Corey Langer, Roger B Cohen, Aditi Singh
  Clinical Lung Cancer. 2024-11-10
• 65 citations
  The Role of Cetuximab for the Treatment of Squamous Cell Carcinoma of the Head and Neck
  Ranee Mehra, Roger B. Cohen, Barbara Burtness
  Clinical Advances in Hematology & Oncology. 2008-10-01
• 16 citations
  A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
  Margaret von Mehren, Carolyn D. Britten, Peter C Pieslor, Wayne Saville, Artemios Vassos
  Investigational New Drugs. 2014-01-24

Journal Articles

• Oncologic Outcomes Following Transoral Robotic Surgery for Human Papillomavirus–Associated Oropharyngeal Carcinoma in Older Patients  
  Harman S Parhar, Karthik Rajasekaran, Ara A Chalian, Christopher H Rassekh, Roger B Cohen, Joshua Bauml, Gregory S Weinstein, Robert M Brody, JAMA Otolaryngology–Head & Neck Surgery
• Cisplatin Versus Cetuximab with Definitive Concurrent Radiotherapy for Head and Neck Squamous Cell Carcinoma: An Analysis of Veterans Health Affairs Data  
  Ravi Vinnakota, Keith Sigel, Joshua M Bauml, Roger B Cohen, Nevena Damjanov, Corey J Langer, Ronac Mamtani, Charu Aggarwal, Christina Knepley, Juan Wisnivesky, Cancer
• Immunotherapy Targeting HPV 16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer  
  Gregory S Weinstein, Charu Aggarwal, Roger B Cohen, Joshua Bauml, Alexander Lin, Clinical Cancer Research

Lectures

• A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses. 
  2019 ASCO Annual Meeting - 6/1/2019
• 10th International Congress on Targeted Therapies in Cancer 
  Physicians' Education Resource, LLC, Washington, Dist Of Col - 8/17/2012